RhumbLine Advisers’s Allogene Therapeutics ALLO Stock Holding History

RhumbLine Advisers’s Portfolio ALLO Stock Details ALLO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$644K	Buy	309,741 +108,714	+54%	+$239K	﹤0.01%	2591
2026 Q1	$490K	Sell	201,027 -1,979	-1%	-$3.97K	﹤0.01%	2624
2025 Q4	$278K	Sell	203,006 -7,720	-4%	-$10.2K	﹤0.01%	3015
2025 Q3	$261K	Buy	210,726 +1,390	+0.7%	+$1.66K	﹤0.01%	3084
2025 Q2	$237K	Buy	209,336 +25,628	+14%	+$34.1K	﹤0.01%	3136
2025 Q1	$268K	Sell	183,708 -8,006	-4%	-$15.1K	﹤0.01%	2954
2024 Q4	$408K	Buy	191,714 +17,527	+10%	+$43.2K	﹤0.01%	2795
2024 Q3	$488K	Buy	174,187 +9,679	+6%	+$25.8K	﹤0.01%	2711
2024 Q2	$383K	Buy	164,508 +12,473	+8%	+$36.8K	﹤0.01%	2849
2024 Q1	$680K	Buy	152,035 +6,074	+4%	+$25.3K	﹤0.01%	2476
2023 Q4	$469K	Buy	145,961 +6,816	+5%	+$19.3K	﹤0.01%	2695
2023 Q3	$441K	Sell	139,145 -5,096	-4%	-$22.3K	﹤0.01%	2681
2023 Q2	$717K	Buy	144,241 +15,009	+12%	+$81.2K	﹤0.01%	2472
2023 Q1	$638K	Buy	129,232 +3,730	+3%	+$23.9K	﹤0.01%	2323
2022 Q4	$789K	Sell	125,502 -3,371	-3%	-$31.2K	﹤0.01%	2256
2022 Q3	$1.39M	Buy	128,873 +10,174	+9%	+$138K	﹤0.01%	1966
2022 Q2	$1.35M	Buy	118,699 +34,281	+41%	+$304K	﹤0.01%	1981
2022 Q1	$769K	Sell	84,418 -5,503	-6%	-$57.3K	﹤0.01%	2238
2021 Q4	$1.34M	Sell	89,921 -847	-0.9%	-$14.9K	﹤0.01%	2082
2021 Q3	$2.33M	Buy	90,768 +2,938	+3%	+$69.8K	﹤0.01%	1816
2021 Q2	$2.29M	Buy	87,830 +26,468	+43%	+$755K	﹤0.01%	1887
2021 Q1	$2.17M	Sell	61,362 -6,034	-9%	-$204K	﹤0.01%	1870
2020 Q4	$1.7M	Buy	67,396 +3,232	+5%	+$105K	﹤0.01%	1923
2020 Q3	$2.42M	Sell	64,164 -11,826	-16%	-$446K	﹤0.01%	1563
2020 Q2	$3.25M	Buy	75,990 +21,406	+39%	+$774K	0.01%	1450
2020 Q1	$1.06M	Buy	54,584 +1,360	+3%	+$32.4K	﹤0.01%	1855
2019 Q4	$1.38M	Buy	53,224 +1,814	+4%	+$50K	﹤0.01%	1945
2019 Q3	$1.4M	Buy	51,410 +118	+0.2%	+$3.36K	﹤0.01%	1892
2019 Q2	$1.38M	Buy	51,292 +19,944	+64%	+$556K	﹤0.01%	1920
2019 Q1	$906K	Buy	31,348 +560	+2%	+$16.2K	﹤0.01%	2087
2018 Q4	$829K	Buy	+30,788	New	+$818K	﹤0.01%	2088

Other funds holding ALLO

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Pfizer New York $170M AUM 191.09% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

TGA

TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return

SCM

Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

RhumbLine Advisers's ALLO Position: Q2 2026 in Review

RhumbLine Advisers increased its Allogene Therapeutics (ALLO) stake by 54% in Q2 2026, buying an estimated $239K and bringing the position to 309,741 shares worth $644K. The position accounts for ﹤0.01% of the portfolio, ranked #2591.

RhumbLine Advisers first reported a position in ALLO in Q4 2018 and has held it in 31 quarters since. The position peaked at $3.25M in Q2 2020. 209 funds tracked by Wall St. Rank hold ALLO as of Q2 2026.

RhumbLine Advisers held 309,741 shares of Allogene Therapeutics worth $644K as of Q2 2026.
RhumbLine Advisers bought 108,714 Allogene Therapeutics shares in Q2 2026, an estimated $239K.
Allogene Therapeutics made up ﹤0.01% of RhumbLine Advisers's portfolio in Q2 2026, its #2591 holding.
RhumbLine Advisers first reported a position in Allogene Therapeutics in Q4 2018 and has held it in 31 quarters since.
RhumbLine Advisers's Allogene Therapeutics position peaked at $3.25M in Q2 2020.
209 funds tracked by Wall St. Rank held Allogene Therapeutics as of Q2 2026.

Based on RhumbLine Advisers's 13F filing for Q2 2026, filed 12 Aug 2026.